Twitter icon
Facebook icon
Instagram icon
YouTube icon
Click to go to mail form
Click to get search form

Hartzler Supports President Trump on Defense Production Act

March 20, 2020
Press Release

WASHINGTON, D.C. – Congresswoman Vicky Hartzler (MO-04) issued the following statement after President Trump signed an executive order invoking the Defense Production Act (DPA) as needed to incentivize American companies to manufacture critical medical resources to address the COVID-19 pandemic:
“This executive order is a decisive action by President Trump to ensure our nation has the health and medical resources needed to respond to the coronavirus. The current public health crisis has shed light on the dangers of our reliance on foreign supply chains for critical medical resources and medicines. If America is to be resilient through crises like these, then we must be able to depend on ourselves and our trusted, proven allies to muster the resources needed to address the threat,” Hartzler said.
“While this executive order gives the Administration the flexibility to utilize the DPA for critical resources like personal protective equipment and ventilators, if necessary, I will continue to encourage the Administration to use its authority under DPA to ensure medical ingredients and raw materials for medications are produced in the United States. Right now, China controls 80% of all ingredients and raw materials going into our generic prescription drugs, allowing them the ability to cut off that supply chain in a moment of conflict. Just as President Trump has worked hard to reduce our dependence on the Middle East for oil, we must continue to reduce our dependence on China for our medical resources as a national security threat.
“In Congress, I have been working with Rep. John Garamendi of California in the House Armed Services Committee to address this very issue. We introduced H.R. 4710, the Pharmaceutical Independence Long-Term Readiness Act, requiring the Department of Defense to look into ways we can stand up American pharmaceutical companies to bolster domestic manufacturing of general prescription drugs used by our servicemembers.  

“I am hopeful we will get this legislation passed as part of the annual National Defense Authorization Act later this year, but hope the president will move forward without it as this is a critical need our nation has which can be addressed through the Defense Production Act," Hartzler concluded.